Company: IPHYF
Filing Date: 2025-04-30
Form Type: 20-F
Source: 0001598599-25-000042
Chunk: 181

Company: Innate Pharma SA
Filing Date: 2025-04-30
Form: 20-F
Item: Item 5
Chunk 181
---
 2024, as compared to a €5.1 million loss for the year ended December 31, 2023. This change mainly results from the net foreign exchange loss of €1.8 million (net foreign exchange gain of €0.9 million in 2023), interest income on financial investments (net gain of €2.4 million in 2024 compared to €3.2 millions in 2023) and the change in the fair value of certain financial instruments (net gain of €2.0 million in 2024 as compared to a net gain of €1.6 million in 2023).

The table below presents the components of our net financial result for the years ended December 31, 2023 and 2024:

                                               Year ended December 31,               
                                                                  2023         2024  
                                                        (in thousands)               
  Interests and gains on financial assets                      € 3,177      € 2,437  
 ─────────────────────────────────────────────────────────────────────────────────────
  Unrealized gains on financials assets                          1,648        1,983  
  Foreign exchange gains                                         2,109        1,658  
  Financial income                                               6,934        6,079  
  Foreign exchange losses                                      (1,195)      (3,409)  
  Interest on financial liabilities                              (640)        (566)  
  Financial expenses                                           (1,835)      (3,975)  
  Net financial income (loss)                                  € 5,099      € 2,104  

For the years ended December 31, 2023 and 2024, the foreign exchange gains and losses mainly result from the variance of the exchange rate between the Euro and the U. S. dollar on U. S. dollar-denominated

cash and cash equivalents, short-term investments, financial assets and collaboration debt based on U. S. dollar. For instruments for which the valuation may be subject to certain events, the Company has ensured that no such events have occurred a of December 31, 2024.

Comparisons for the years ended December 31, 2022 and 2023

The following table sets forth a summary of our consolidated statements of income (loss) for the periods presented.

                                                           Year ended December 31,                 
                                                                              2022           2023  
                                                                    (in thousands)                 
  Revenue from collaboration and licensing agreements                     € 49,580       €